393 research outputs found
Oncoplastic conservative surgery for breast cancer: long-term outcomes of our first ten years experience
The main goal of oncoplastic breast surgery (OBS) is to optimize cosmetic outcomes and reduce patient morbidity, while still providing an oncologically-safe surgical outcome and extending the target population of conservative surgery. Although the growing number of reported experiences with oncoplastic surgery, few studies account for the long-term outcomes
Oncological safety of stromal vascular fraction enriched fat grafting in two-stage breast reconstruction after nipple sparing mastectomy: long-term results of a prospective study
OBJECTIVE: Autologous fat transfer (AFT) is commonly used to treat implant palpability and prevent fibrosis and thinning in mastectomy skin flaps. A major limit to this procedure is volume retention over time, leading to the introduction of fat enrichment with stromal vascular fraction (SVF+AFT). Oncological concerns have been raised over the injection of an increased concentration of progenitors cells (ASCs) in the SVF. The aim of the study is to evaluate the long-term cancer recurrence risk of SVF+AFT cases compared to AFT, in patients undergoing Nipple Sparing Mastectomy (NSM). PATIENTS AND METHODS: A prospective study was designed to compare three groups of patients undergoing NSM followed by SVF+AFT, AFT or none (control group), after a two-stage breast reconstruction. Patients were strictly followed-up for at least 5-years from the second stage reconstructive procedure. Loco-regional and systemic recurrence rate were evaluated over time as the primary outcome. Logistic regression was used to investigate which factors were associated with recurrence events and independent variables of interest were: surgical technique, age above 50 years old, lympho-vascular invasion, oncological stage, adjuvant or neoadjuvant chemotherapy, adjuvant radiotherapy and adjuvant hormone therapy. RESULTS: 41 women were included in G1 (SVF+AFT), 64 in G2 (AFT), and 64 in G3 (control group). Loco-regional recurrence rate was 2.4% for G1, 4.7% for G2, and 1.6% for G3. Systemic recurrence was 7.3%, 3.1%, and 3.1%, respectively. Among the variables included, there were no significant risk factors influencing a recurrence event, either loco-regional or systemic. In particular, SVF+AFT (G1) did not increase the oncological recurrence. CONCLUSIONS: Our data suggest that both centrifuged and SVF-enhanced fat transfer have a similar safety level in comparison to patients who did not undergo fat grafting in breast reconstruction after NSM
Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia
Background Evidence suggests that LPA risk genotypes are a possible contributor to the clinical diagnosis of familial hypercholesterolemia (FH). This study aimed at determining the prevalence of LPA risk variants in adult individuals with FH enrolled in the Italian LIPIGEN (Lipid Transport Disorders Italian Genetic Network) study, with (FH/M+) or without (FH/M-) a causative genetic variant. Methods and ResultsAn lp(a) [lipoprotein(a)] genetic score was calculated by summing the number risk-increasing alleles inherited at rs3798220 and rs10455872 variants. Overall, in the 4.6% of 1695 patients with clinically diagnosed FH, the phenotype was not explained by a monogenic or polygenic cause but by genotype associated with high lp(a) levels. Among 765 subjects with FH/M- and 930 subjects with FH/M+, 133 (17.4%) and 95 (10.2%) were characterized by 1 copy of either rs10455872 or rs3798220 or 2 copies of either rs10455872 or rs3798220 (lp(a) score >= 1). Subjects with FH/M- also had lower mean levels of pretreatment low-density lipoprotein cholesterol than individuals with FH/M+ (t test for difference in means between FH/M- and FH/M+ groups <0.0001); however, subjects with FH/M- and lp(a) score >= 1 had higher mean (SD) pretreatment low-density lipoprotein cholesterol levels (223.47 [50.40] mg/dL) compared with subjects with FH/M- and lp(a) score=0 (219.38 [54.54] mg/dL for), although not statistically significant. The adjustment of low-density lipoprotein cholesterol levels based on lp(a) concentration reduced from 68% to 42% the proportion of subjects with low-density lipoprotein cholesterol level >= 190 mg/dL (or from 68% to 50%, considering a more conservative formula). ConclusionsOur study supports the importance of measuring lp(a) to perform the diagnosis of FH appropriately and to exclude that the observed phenotype is driven by elevated levels of lp(a) before performing the genetic test for FH
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study
Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study
Background and aims: We aimed to describe the limitations of familiar hypercholesterolemia (FH) diagnosis in childhood based on the presence of the typical features of FH, such as physical sings of cholesterol accumulation and personal or family history of premature cardiovascular disease or hypercholesterolemia, comparing their prevalence in the adult and paediatric FH population, and to illustrate how additional information can lead to a more effective diagnosis of FH at a younger age. Methods: From the Italian LIPIGEN cohort, we selected 1188 (≥18 years) and 708 (<18 years) genetically-confirmed heterozygous FH, with no missing personal FH features. The prevalence of personal and familial FH features was compared between the two groups. For a sub-group of the paediatric cohort (N = 374), data about premature coronary heart disease (CHD) in second-degree family members were also included in the evaluation. Results: The lower prevalence of typical FH features in children/adolescents vs adults was confirmed: the prevalence of tendon xanthoma was 2.1% vs 13.1%, and arcus cornealis was present in 1.6% vs 11.2% of the cohorts, respectively. No children presented clinical history of premature CHD or cerebral/peripheral vascular disease compared to 8.8% and 5.6% of adults, respectively. The prevalence of premature CHD in first-degree relatives was significantly higher in adults compared to children/adolescents (38.9% vs 19.7%). In the sub-cohort analysis, a premature CHD event in parents was reported in 63 out of 374 subjects (16.8%), but the percentage increased to 54.0% extending the evaluation also to second-degree relatives. Conclusions: In children, the typical FH features are clearly less informative than in adults. A more thorough data collection, adding information about second-degree relatives, could improve the diagnosis of FH at younger age
Advanced Virgo Plus: Future Perspectives
While completing the commissioning phase to prepare the Virgo interferometer for the next joint Observation Run (O4), the Virgo collaboration is also finalizing the design of the next upgrades to the detector to be employed in the following Observation Run (O5). The major upgrade will concern decreasing the thermal noise limit, which will imply using very large test masses and increased laser beam size. But this will not be the only upgrade to be implemented in the break between the O4 and O5 observation runs to increase the Virgo detector strain sensitivity. The paper will cover the challenges linked to this upgrade and implications on the detector's reach and observational potential, reflecting the talk given at 12th Cosmic Ray International Seminar - CRIS 2022 held in September 2022 in Napoli
Virgo Detector Characterization and Data Quality during the O3 run
The Advanced Virgo detector has contributed with its data to the rapid growth
of the number of detected gravitational-wave signals in the past few years,
alongside the two LIGO instruments. First, during the last month of the
Observation Run 2 (O2) in August 2017 (with, most notably, the compact binary
mergers GW170814 and GW170817) and then during the full Observation Run 3 (O3):
an 11 months data taking period, between April 2019 and March 2020, that led to
the addition of about 80 events to the catalog of transient gravitational-wave
sources maintained by LIGO, Virgo and KAGRA. These discoveries and the manifold
exploitation of the detected waveforms require an accurate characterization of
the quality of the data, such as continuous study and monitoring of the
detector noise. These activities, collectively named {\em detector
characterization} or {\em DetChar}, span the whole workflow of the Virgo data,
from the instrument front-end to the final analysis. They are described in
details in the following article, with a focus on the associated tools, the
results achieved by the Virgo DetChar group during the O3 run and the main
prospects for future data-taking periods with an improved detector.Comment: 86 pages, 33 figures. This paper has been divided into two articles
which supercede it and have been posted to arXiv on October 2022. Please use
these new preprints as references: arXiv:2210.15634 (tools and methods) and
arXiv:2210.15633 (results from the O3 run
Virgo Detector Characterization and Data Quality: tools
Detector characterization and data quality studies -- collectively referred
to as {\em DetChar} activities in this article -- are paramount to the
scientific exploitation of the joint dataset collected by the LIGO-Virgo-KAGRA
global network of ground-based gravitational-wave (GW) detectors. They take
place during each phase of the operation of the instruments (upgrade, tuning
and optimization, data taking), are required at all steps of the dataflow (from
data acquisition to the final list of GW events) and operate at various
latencies (from near real-time to vet the public alerts to offline analyses).
This work requires a wide set of tools which have been developed over the years
to fulfill the requirements of the various DetChar studies: data access and
bookkeeping; global monitoring of the instruments and of the different steps of
the data processing; studies of the global properties of the noise at the
detector outputs; identification and follow-up of noise peculiar features
(whether they be transient or continuously present in the data); quick
processing of the public alerts. The present article reviews all the tools used
by the Virgo DetChar group during the third LIGO-Virgo Observation Run (O3,
from April 2019 to March 2020), mainly to analyse the Virgo data acquired at
EGO. Concurrently, a companion article focuses on the results achieved by the
DetChar group during the O3 run using these tools.Comment: 44 pages, 16 figures. To be submitted to Class. and Quantum Grav.
This is the "Tools" part of preprint arXiv:2205.01555 [gr-qc] which has been
split into two companion articles: one about the tools and methods, the other
about the analyses of the O3 Virgo dat
Virgo Detector Characterization and Data Quality: results from the O3 run
The Advanced Virgo detector has contributed with its data to the rapid growth
of the number of detected gravitational-wave (GW) signals in the past few
years, alongside the two Advanced LIGO instruments. First during the last month
of the Observation Run 2 (O2) in August 2017 (with, most notably, the compact
binary mergers GW170814 and GW170817), and then during the full Observation Run
3 (O3): an 11-months data taking period, between April 2019 and March 2020,
that led to the addition of about 80 events to the catalog of transient GW
sources maintained by LIGO, Virgo and now KAGRA. These discoveries and the
manifold exploitation of the detected waveforms require an accurate
characterization of the quality of the data, such as continuous study and
monitoring of the detector noise sources. These activities, collectively named
{\em detector characterization and data quality} or {\em DetChar}, span the
whole workflow of the Virgo data, from the instrument front-end hardware to the
final analyses. They are described in details in the following article, with a
focus on the results achieved by the Virgo DetChar group during the O3 run.
Concurrently, a companion article describes the tools that have been used by
the Virgo DetChar group to perform this work.Comment: 57 pages, 18 figures. To be submitted to Class. and Quantum Grav.
This is the "Results" part of preprint arXiv:2205.01555 [gr-qc] which has
been split into two companion articles: one about the tools and methods, the
other about the analyses of the O3 Virgo dat
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study
Background and aims: Familial hypercholesterolemia (FH) is an inherited disorder characterized by high levels of blood cholesterol from birth and premature coronary heart disease. Thus, the identification of FH patients is crucial to prevent or delay the onset of cardiovascular events, and the availability of a tool helping with the diagnosis in the setting of general medicine is essential to improve FH patient identification.Methods: This study evaluated the performance of the Dutch Lipid Clinic Network (DLCN) score in FH patients enrolled in the LIPIGEN study, an Italian integrated network aimed at improving the identification of patients with genetic dyslipidaemias, including FH.Results: The DLCN score was applied on a sample of 1377 adults (mean age 42.9 +/- 14.2 years) with genetic diagnosis of FH, resulting in 28.5% of the sample classified as probable FH and 37.9% as classified definite FH. Among these subjects, 43.4% had at least one missing data out of 8, and about 10.0% had 4 missing data or more. When analyzed based on the type of missing data, a higher percentage of subjects with at least 1 missing data in the clinical history or physical examination was classified as possible FH (DLCN score 3-5). We also found that using real or estimated pre-treatment LDL-C levels may significantly modify the DLCN score.Conclusions: Although the DLCN score is a useful tool for physicians in the diagnosis of FH, it may be limited by the complexity to retrieve all the essential information, suggesting a crucial role of the clinical judgement in the identification of FH subjects
- …